The potential of the tumor microenvironment to influence Apo2L/TRAIL induced apoptosis

Thomas A. Mace, Nariyuke Yamane, Jinrong Cheng, Bonnie L. Hylander, Elizabeth A. Repasky

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Apo2L/TRAIL ligation of specific cell surface receptors (DR4 and DR5) induces apoptosis of many malignant cells with little effect on normal cells. This anti-tumor capability has been demonstrated using cell lines of many tumor types, both in vitro and in vivo when the cells are grown as xenografts. We have extended these studies to investigate the efficacy of Apo2L/TRAIL against patient tumor xenografts in SCID mice and found that the growth of many tumors, both of primary and metastatic origin, can be inhibited by Apo2L/TRAIL. The basis of resistance to Apo2L/TRAIL induced apoptosis in malignant cells and normal cells is not completely understood, but it is known that a variety of factors including hypoxia, MMPs and cytokines present in the tumor microenvironment can influence the response of malignant cells to Apo2L/TRAIL. Currently, the clinical potential of several molecules targeting the Apo2L/TRAIL receptors DR4 and DR5 is being investigated. Our goal in this review is to provide a brief overview of a number of factors that have potential to influence the response of patient tumors to Apo2L/TRAIL.

Original languageEnglish (US)
Pages (from-to)279-296
Number of pages18
JournalImmunological Investigations
Volume35
Issue number3-4
DOIs
StatePublished - Dec 1 2006
Externally publishedYes

Fingerprint

Tumor Microenvironment
Apoptosis
Heterografts
Neoplasms
TNF-Related Apoptosis-Inducing Ligand Receptors
SCID Mice
Cell Surface Receptors
Tumor Cell Line
Matrix Metalloproteinases
Ligation
Cytokines
Growth

Keywords

  • Apo2L/TRAIL
  • Hypoxia
  • Tumor infiltrating leukocytes
  • Tumor microenvironment
  • Tumor vasculature

ASJC Scopus subject areas

  • Immunology

Cite this

The potential of the tumor microenvironment to influence Apo2L/TRAIL induced apoptosis. / Mace, Thomas A.; Yamane, Nariyuke; Cheng, Jinrong; Hylander, Bonnie L.; Repasky, Elizabeth A.

In: Immunological Investigations, Vol. 35, No. 3-4, 01.12.2006, p. 279-296.

Research output: Contribution to journalReview article

Mace, Thomas A. ; Yamane, Nariyuke ; Cheng, Jinrong ; Hylander, Bonnie L. ; Repasky, Elizabeth A. / The potential of the tumor microenvironment to influence Apo2L/TRAIL induced apoptosis. In: Immunological Investigations. 2006 ; Vol. 35, No. 3-4. pp. 279-296.
@article{4a4d43c60dfd4b6f9f32113dc6f87320,
title = "The potential of the tumor microenvironment to influence Apo2L/TRAIL induced apoptosis",
abstract = "Apo2L/TRAIL ligation of specific cell surface receptors (DR4 and DR5) induces apoptosis of many malignant cells with little effect on normal cells. This anti-tumor capability has been demonstrated using cell lines of many tumor types, both in vitro and in vivo when the cells are grown as xenografts. We have extended these studies to investigate the efficacy of Apo2L/TRAIL against patient tumor xenografts in SCID mice and found that the growth of many tumors, both of primary and metastatic origin, can be inhibited by Apo2L/TRAIL. The basis of resistance to Apo2L/TRAIL induced apoptosis in malignant cells and normal cells is not completely understood, but it is known that a variety of factors including hypoxia, MMPs and cytokines present in the tumor microenvironment can influence the response of malignant cells to Apo2L/TRAIL. Currently, the clinical potential of several molecules targeting the Apo2L/TRAIL receptors DR4 and DR5 is being investigated. Our goal in this review is to provide a brief overview of a number of factors that have potential to influence the response of patient tumors to Apo2L/TRAIL.",
keywords = "Apo2L/TRAIL, Hypoxia, Tumor infiltrating leukocytes, Tumor microenvironment, Tumor vasculature",
author = "Mace, {Thomas A.} and Nariyuke Yamane and Jinrong Cheng and Hylander, {Bonnie L.} and Repasky, {Elizabeth A.}",
year = "2006",
month = "12",
day = "1",
doi = "10.1080/08820130600745463",
language = "English (US)",
volume = "35",
pages = "279--296",
journal = "Immunological Investigations",
issn = "0882-0139",
publisher = "Informa Healthcare",
number = "3-4",

}

TY - JOUR

T1 - The potential of the tumor microenvironment to influence Apo2L/TRAIL induced apoptosis

AU - Mace, Thomas A.

AU - Yamane, Nariyuke

AU - Cheng, Jinrong

AU - Hylander, Bonnie L.

AU - Repasky, Elizabeth A.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Apo2L/TRAIL ligation of specific cell surface receptors (DR4 and DR5) induces apoptosis of many malignant cells with little effect on normal cells. This anti-tumor capability has been demonstrated using cell lines of many tumor types, both in vitro and in vivo when the cells are grown as xenografts. We have extended these studies to investigate the efficacy of Apo2L/TRAIL against patient tumor xenografts in SCID mice and found that the growth of many tumors, both of primary and metastatic origin, can be inhibited by Apo2L/TRAIL. The basis of resistance to Apo2L/TRAIL induced apoptosis in malignant cells and normal cells is not completely understood, but it is known that a variety of factors including hypoxia, MMPs and cytokines present in the tumor microenvironment can influence the response of malignant cells to Apo2L/TRAIL. Currently, the clinical potential of several molecules targeting the Apo2L/TRAIL receptors DR4 and DR5 is being investigated. Our goal in this review is to provide a brief overview of a number of factors that have potential to influence the response of patient tumors to Apo2L/TRAIL.

AB - Apo2L/TRAIL ligation of specific cell surface receptors (DR4 and DR5) induces apoptosis of many malignant cells with little effect on normal cells. This anti-tumor capability has been demonstrated using cell lines of many tumor types, both in vitro and in vivo when the cells are grown as xenografts. We have extended these studies to investigate the efficacy of Apo2L/TRAIL against patient tumor xenografts in SCID mice and found that the growth of many tumors, both of primary and metastatic origin, can be inhibited by Apo2L/TRAIL. The basis of resistance to Apo2L/TRAIL induced apoptosis in malignant cells and normal cells is not completely understood, but it is known that a variety of factors including hypoxia, MMPs and cytokines present in the tumor microenvironment can influence the response of malignant cells to Apo2L/TRAIL. Currently, the clinical potential of several molecules targeting the Apo2L/TRAIL receptors DR4 and DR5 is being investigated. Our goal in this review is to provide a brief overview of a number of factors that have potential to influence the response of patient tumors to Apo2L/TRAIL.

KW - Apo2L/TRAIL

KW - Hypoxia

KW - Tumor infiltrating leukocytes

KW - Tumor microenvironment

KW - Tumor vasculature

UR - http://www.scopus.com/inward/record.url?scp=33747586281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747586281&partnerID=8YFLogxK

U2 - 10.1080/08820130600745463

DO - 10.1080/08820130600745463

M3 - Review article

C2 - 16916755

AN - SCOPUS:33747586281

VL - 35

SP - 279

EP - 296

JO - Immunological Investigations

JF - Immunological Investigations

SN - 0882-0139

IS - 3-4

ER -